ASH 2017 | MRD measurement: next-generation sequencing or flow cytometry?
Minimal residual disease (MRD) has become a major tool in the monitoring of hematological malignancies; however, its utility can be hampered by limitations in the methodology of its measurement. In this interview, Irene Ghobrial, MD, from the Dana-Farber Cancer Institute, Boston, MA explains the primary methods of determining MRD and offers her thoughts on the future use of MRD in multiple myeloma (MM). This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up